Alzamend Neuro

Alzamend Neuro is a clinical-stage biopharmaceutical company headquartered in Atlanta, Georgia, dedicated to developing and commercializing treatments for Alzheimer's disease and psychiatric disorders. They have a mission of "Making Alzheimer's Just a Memory" and are committed to addressing the unmet needs of patients affected by these conditions. Their current pipeline consists of two novel drug candidates: AL001, a patented ionic cocrystal technology delivering lithium for the treatment of Alzheimer's, bipolar disorder, major depressive disorder, and post-traumatic stress disorder, and ALZN002, a patented immunotherapy vaccine that aims to restore the immune system's ability to combat Alzheimer's.

Alzamend Neuro has made significant progress in its clinical development, with AL001 completing Phase IIA trials and ALZN002 entering Phase I/IIA trials. They are committed to advancing these therapies through rigorous scientific research and collaboration with leading institutions like the University of South Florida Research Foundation and Massachusetts General Hospital. Their focus on innovative treatments and a strong belief in the power of research positions them as a key player in the fight against Alzheimer's and other neurodegenerative diseases.

Alzamend Neuro is a clinical-stage biopharmaceutical company dedicated to developing and marketing safe and effective treatments for Alzheimer's disease and psychiatric disorders. Driven by a commitment to "Making Alzheimer's Just a Memory™," they leverage patented technologies and research to address the unmet needs of patients suffering from these debilitating conditions. Their pipeline includes innovative drug candidates like AL001, a lithium-based treatment for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD, and ALZN002, an immunotherapy designed to combat Alzheimer's by restoring the body's immune response.

Alzamend Neuro promotes a culture driven by innovation and a commitment to finding treatments and cures for Alzheimer's and other neurological disorders. The company values strong research and development, as evidenced by its focus on clinical trials and partnerships with institutions like Massachusetts General Hospital. The company also fosters a collaborative environment by encouraging employees to share information and engage in open communication. Alzamend Neuro's mission is to provide hope to patients and their families, creating a work environment that emphasizes dedication and a shared passion for improving lives.

Alzamend Neuro is committed to diversity, equity, and inclusion, as evidenced by its Board Diversity Matrix. The matrix publicly discloses the gender identity and demographic background of the Board of Directors. As of December 31st, 2023, the board consists of 7 members, including 1 female director, 1 African American or Black director, and 1 Asian director. This data demonstrates their active effort to build a diverse board, although the company does not explicitly state its broader approach to diversity, equity, and inclusion throughout the organization.